NCT05834946

Brief Summary

This prospective parallel, double-blind, four-arm randomised controlled clinical study is planned to assess the difference in the level of the inflammatory biomarkers expressed following the placement of the first dental implant in patients with history of periodontitis (successfully treated) and healthy controls without the disease, during implant osseointegration period. The subjects in both groups will also be randomised to receive one of the two types of implants provided which have different surface treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
29

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 4, 2021

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

January 17, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

April 28, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2025

Completed
Last Updated

October 18, 2023

Status Verified

April 1, 2023

Enrollment Period

2.2 years

First QC Date

January 17, 2023

Last Update Submit

October 17, 2023

Conditions

Keywords

dental implanthistory of periodontitismatrix metalloproteinase (MMP)-8histological analysisnext generation sequencingdental plaquegingival crevicular fluidsperi-implant sulcular fluidsperi-implant soft tissueproteomic analysis

Outcome Measures

Primary Outcomes (1)

  • Level of matrix metalloproteinase (MMP)-8 expressed in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement

    To measure the absolute quantification of MMP-8 level expressed during the implant osseointegration period in all study groups via ELISA method.

    From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) and 3-months after implant crown restoration (final visit- TP4)

Secondary Outcomes (4)

  • Shift of the microbial composition in the supragingival dental plaque, identified via 16S rRNA next generation sequencing

    From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)

  • Shift of proteome profiles in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement

    From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)

  • Histological changes in the peri-implant soft tissue before and after implant placement

    Between first stage (baseline/pre) and second stage implant surgery (post-operative) at 3 months after the first surgery

  • Changes in the clinical parameters during the early-stage implant placement

    From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)

Study Arms (4)

Group T-A

EXPERIMENTAL

7 patients with history of periodontitis

Other: Megagen implant placement

Group T-B

EXPERIMENTAL

7 patients with history of periodontitis

Other: Biomate-Swiss implant

Group C-A

ACTIVE COMPARATOR

7 patients without history of periodontitis

Other: Megagen implant placement

Group C-B

ACTIVE COMPARATOR

8 patients without history of periodontitis

Other: Biomate-Swiss implant

Interventions

Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface

Group C-AGroup T-A

Biomate-Swiss implant with precision dimension laser (PDL) surface

Group C-BGroup T-B

Eligibility Criteria

Age30 Years - 65 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsFemale and male
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • History of periodontitis but currently stable
  • Must have successfully completed active periodontal treatment at least 4 months prior to the commencement of study
  • No history of periodontitis, with minimal age-related radiographic bone loss
  • Reason for losing the tooth/teeth was not due to periodontal problem
  • Medically healthy
  • Aged between 30 to 65 years old
  • Non-smoker, or quit smoking at least 12 months before study commencement
  • Good oral hygiene (full mouth plaque score (FMPS)\<20%, full mouth bleeding score (FMBS)\<15%)
  • Indicated for a single implant placement in the posterior region, with adjacent and contralateral natural tooth
  • Intact inter-cuspal position

You may not qualify if:

  • Previous history of dental implant placement
  • Currently pregnant or intend to be pregnant, and/or lactating mothers
  • Taking long-term medicines which may affect gingival tissue and oral microbiome, e.g. antibiotics, anticoagulants, anticonvulsants, immunosuppressants and calcium channel blockers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Dentistry, University of Malaya

Kuala Lumpur, Kuala Lumpur, 50603, Malaysia

Location

MeSH Terms

Conditions

PeriodontitisPeri-ImplantitisDental Plaque

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesDental DepositsTooth Diseases

Study Officials

  • Norul H Mohamad-Hassan, DDS,MCD

    University of Malaya

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
All participants will be blinded from the randomisation. An opaque envelope will be used to conceal the implant designation and will only be revealed to the operator after the site is ready for implant placement. A blinded researcher will be assigned as clinical assessor who will not be involved with the surgical procedure, subject recruitment nor consent taking. An assistant who is not involved with the research will also be asked to re-code the sample tubes to ensure blinding for data/sample analysis.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Test group: Patient with history of periodontitis Control group: Patient without history of periodontitis Patients in both groups will be randomised to receive one of two type of implants with different surface characteristics.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 17, 2023

First Posted

April 28, 2023

Study Start

March 4, 2021

Primary Completion

May 30, 2023

Study Completion

May 30, 2025

Last Updated

October 18, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in this article after deidentification. Researchers should provide a methodologically sound proposal and directed to the principal investigator by email.

Time Frame
Beginning 3 months and ending 5 years following article(s) publication.
Access Criteria
To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement.

Locations